Advanced search
Combine gene, variant, phenotype, region and year filters
Every result shows the extracted entities next to the sentences that support them; rows for the searched entities come first.
Transparent by designEvery result links extracted entities to its source sentence and publication identifier.
Knowledge-base search
About your search
SIRT1 and ulcerative colitis are reported together in 7 articles.
Gene
SIRT1
- HGNC
- HGNC:14929
104articles
104mentions
6variants with confirmed gene link
Most co-reported phenotypes (articles)
diabetes mellitus 18ulcerative colitis 7breast cancer 5cardiomyopathy 5inflammatory bowel disease 5intellectual disability 5Parkinson disease 4obesity 4
Reported variants (articles · ClinVar status)
Phenotype
Ulcerative colitis
492articles
492mentions
12co-reported genes shown
Most co-reported genes (articles)
Counts are literature co-mentions in SaudiVarKB, not clinical or causal assertions. Gene details: HGNC; variant status: ClinVar via dbSNP.
Publications
7 records shown · first 60Modulation of mTOR, NLRP3, and Nrf2/HO-1 signaling by atorvastatin and nitazoxanide in experimental ulcerative colitis.
PMID 41888416 | DOI 10.1007/s00210-026-05242-8 · Naunyn-Schmiedeberg's archives of pharmacology · 2026 · 5 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | SIRT1 | “Tissue levels of SIRT1, mTOR, HO-1, Nrf2, STAT3, AMPK, and Dickkopf-related protein 1 (DKK1) were measured, along with colonic gene expression of NLRP3, Wnt, IL-6, TNF-α, and DKK1.” | 0.98 | hgnc_dict_v1 |
| phenotype | ulcerative colitis | “Modulation of mTOR, NLRP3, and Nrf2/HO-1 signaling by atorvastatin and nitazoxanide in experimental ulcerative colitis.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | NLRP3 | “Modulation of mTOR, NLRP3, and Nrf2/HO-1 signaling by atorvastatin and nitazoxanide in experimental ulcerative colitis.” | 0.98 | hgnc_dict_v1 |
| gene | STAT3 | “However, substantial evidence implicates multiple signaling pathways in its pathogenesis, including interleukin-6 (IL-6)/signal transducer and activator of transcription 3 (STAT3), wingless/Int1 (Wnt), heme oxygenase-1 (HO-1), nuclear factor erythroid 2-related factor 2 (Nrf2), adenosine monophosphate-activated protein kinase (AMPK), mammalian target of rapamycin (mTOR), and NLR family pyrin domain-containing 3 (NLRP3).” | 0.98 | hgnc_dict_v1 |
Fenofibrate as an Adjunct Therapy for Ulcerative Colitis: Targeting Inflammation via SIRT1, NLRP3, and AMPK Pathways: A Randomized Controlled Pilot Study.
PMID 39575188 | PMCID PMC11578921 | DOI 10.2147/DDDT.S490772 · Drug design, development and therapy · 2024 · 4 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | SIRT1 | “Fenofibrate as an Adjunct Therapy for Ulcerative Colitis: Targeting Inflammation via SIRT1, NLRP3, and AMPK Pathways: A Randomized Controlled Pilot Study.” | 0.98 | hgnc_dict_v1 |
| phenotype | ulcerative colitis | “Fenofibrate as an Adjunct Therapy for Ulcerative Colitis: Targeting Inflammation via SIRT1, NLRP3, and AMPK Pathways: A Randomized Controlled Pilot Study.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | NLRP3 | “Fenofibrate as an Adjunct Therapy for Ulcerative Colitis: Targeting Inflammation via SIRT1, NLRP3, and AMPK Pathways: A Randomized Controlled Pilot Study.” | 0.98 | hgnc_dict_v1 |
| phenotype | inflammatory bowel disease | “A gastroenterologist assessed patients by non-invasive Partial Mayo Score (PMS) and the Inflammatory Bowel Disease Questionnaire (IBDQ) to evaluate clinical response and remission.” | 0.98 | phenotype_alias_lexicon_v2 |
Activation of AMPK/SIRT1/FOXO3a signaling by BMS-477118 (saxagliptin) mitigates chronic colitis in rats: uncovering new anti-inflammatory and antifibrotic roles.
PMID 39359253 | PMCID PMC11445602 | DOI 10.3389/fphar.2024.1456058 · Frontiers in pharmacology · 2024 · 3 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | SIRT1 | “Activation of AMPK/SIRT1/FOXO3a signaling by BMS-477118 (saxagliptin) mitigates chronic colitis in rats: uncovering new anti-inflammatory and antifibrotic roles.” | 0.98 | hgnc_dict_v1 |
| phenotype | ulcerative colitis | “Ulcerative colitis (UC) is a debilitating chronic disease marked by persistent inflammation and intestinal fibrosis.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | DPP4 | “BMS-477118, a reversible inhibitor of dipeptidyl peptidase 4 (DPP4), has demonstrated anti-inflammatory properties in preclinical and clinical studies with minimal adverse effects compared to other antidiabetic agents.” | 0.98 | hgnc_dict_v1 |
Canagliflozin ameliorates ulcerative colitis via regulation of TLR4/MAPK/NF-κB and Nrf2/PPAR-γ/SIRT1 signaling pathways.
PMID 37898288 | DOI 10.1016/j.ejphar.2023.176166 · European journal of pharmacology · 2023 · 5 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | SIRT1 | “Canagliflozin ameliorates ulcerative colitis via regulation of TLR4/MAPK/NF-κB and Nrf2/PPAR-γ/SIRT1 signaling pathways.” | 0.98 | hgnc_dict_v1 |
| phenotype | ulcerative colitis | “Canagliflozin ameliorates ulcerative colitis via regulation of TLR4/MAPK/NF-κB and Nrf2/PPAR-γ/SIRT1 signaling pathways.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | TLR4 | “Canagliflozin ameliorates ulcerative colitis via regulation of TLR4/MAPK/NF-κB and Nrf2/PPAR-γ/SIRT1 signaling pathways.” | 0.98 | hgnc_dict_v1 |
| gene | IRF3 | “Canagliflozin attenuates inflammation in AA-induced colitis, evidenced by significant and dose-dependently downregulation of p38 MAPK, NF-κB-p65, IKK, IRF3, and NADPH-oxidase as well as colonic levels of IL-6 and IL-1β and MPO enzymatic activity.” | 0.98 | hgnc_dict_v1 |
Correction to: Umbelliferone ameliorates ulcerative colitis induced by acetic acid via modulation of TLR4/NF‑κB‑p65/iNOS and SIRT1/PPARγ signaling pathways in rats.
PMID 36746866 | DOI 10.1007/s11356-023-25751-w · Environmental science and pollution research international · 2023 · 3 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | SIRT1 | “Correction to: Umbelliferone ameliorates ulcerative colitis induced by acetic acid via modulation of TLR4/NF‑κB‑p65/iNOS and SIRT1/PPARγ signaling pathways in rats.” | 0.98 | hgnc_dict_v1 |
| phenotype | ulcerative colitis | “Correction to: Umbelliferone ameliorates ulcerative colitis induced by acetic acid via modulation of TLR4/NF‑κB‑p65/iNOS and SIRT1/PPARγ signaling pathways in rats.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | TLR4 | “Correction to: Umbelliferone ameliorates ulcerative colitis induced by acetic acid via modulation of TLR4/NF‑κB‑p65/iNOS and SIRT1/PPARγ signaling pathways in rats.” | 0.98 | hgnc_dict_v1 |
Targeting SIRT1/FoxO3a/Nrf2 and PI3K/AKT Pathways with Rebamipide Attenuates Acetic Acid-Induced Colitis in Rats.
PMID 37111290 | PMCID PMC10142103 | DOI 10.3390/ph16040533 · Pharmaceuticals (Basel, Switzerland) · 2023 · 3 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | SIRT1 | “Targeting SIRT1/FoxO3a/Nrf2 and PI3K/AKT Pathways with Rebamipide Attenuates Acetic Acid-Induced Colitis in Rats.” | 0.98 | hgnc_dict_v1 |
| phenotype | ulcerative colitis | “Hence, the current study aimed to investigate the ameliorative effect of rebamipide in a rat model of acetic acid-evoked ulcerative colitis and the linked mechanisms pertaining to SIRT1/FoxO3a/Nrf2 and PI3K/AKT pathways.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | CRP | “The favorable outcomes of rebamipide were driven by combating inflammation evidenced by dampening the colonic expression of NF-κBp65 and the pro-inflammatory markers CRP, TNF-α, and IL-6.” | 0.98 | hgnc_dict_v1 |
Umbelliferone ameliorates ulcerative colitis induced by acetic acid via modulation of TLR4/NF-κB-p65/iNOS and SIRT1/PPARγ signaling pathways in rats.
PMID 35066822 | DOI 10.1007/s11356-021-18252-1 · Environmental science and pollution research international · 2022 · 5 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | SIRT1 | “Umbelliferone ameliorates ulcerative colitis induced by acetic acid via modulation of TLR4/NF-κB-p65/iNOS and SIRT1/PPARγ signaling pathways in rats.” | 0.98 | hgnc_dict_v1 |
| phenotype | ulcerative colitis | “Umbelliferone ameliorates ulcerative colitis induced by acetic acid via modulation of TLR4/NF-κB-p65/iNOS and SIRT1/PPARγ signaling pathways in rats.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | TLR4 | “Umbelliferone ameliorates ulcerative colitis induced by acetic acid via modulation of TLR4/NF-κB-p65/iNOS and SIRT1/PPARγ signaling pathways in rats.” | 0.98 | hgnc_dict_v1 |
| gene | MPO | “Mechanistically, UMB reduced the elevated colonic TNF-α, IL-6, MPO, and VCAM-1 and downregulated the gene and protein expression of TLR4, NF-κB, and iNOS signaling factors, exhibiting potent anti-inflammatory effects.” | 0.98 | hgnc_dict_v1 |